TABLE 1.
Data on demographics of the cats (FAS population)
| Pimobendan (n = 39) | Placebo (n = 37) | |
|---|---|---|
| Sex a | ||
| Female | 8 (20%) | 10 (27%) |
| Male | 31 (80%) | 27 (73%) |
| BW (kg) | 5.30 ± 2.23 | 5.20 ± 1.54 |
| Age (year) | 6.50 ± 4.68 | 6.40 ± 4.37 |
| LVOTO – yes | 3.7 ± 2.67 | 4.4 ± 3.42 |
| LVOTO – no | 8.1 ± 4.87 | 7.7 ± 4.52 |
| Time since 1st diagnosis b (days) | 12.1 ± 19.5 | 12.8 ± 20.2 |
Note: Group LVOTO – yes and pimobendan (n = 14), group LVOTO – yes and placebo (n = 15), Group LVOTO – no and pimobendan (n = 25), and group LVOTO – no and placebo (n = 22).
Abbreviations: BW, body weight; FAS, full analysis set; LVOTO, left ventricular outflow tract obstruction.
a
97% of cats were neutered or spayed. Absolute and relative frequencies as well as means and standard deviations are presented.
b
Mean (±SD) time between identification and stabilization of CHF and enrollment.